for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Wave Life Sciences Ltd

WVE.OQ

Latest Trade

10.93USD

Change

-4.91(-31.00%)

Volume

1,659,736

Today's Range

10.80

 - 

11.23

52 Week Range

6.61

 - 

39.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.84
Open
10.93
Volume
1,659,736
3M AVG Volume
14.32
Today's High
11.23
Today's Low
10.80
52 Week High
39.97
52 Week Low
6.61
Shares Out (MIL)
36.45
Market Cap (MIL)
552.77
Forward P/E
-4.11
Dividend (Yield %)
--

Latest Developments

More

Wave Life Sciences Reports Second Quarter 2020 Financial Results And Provides Business Update

Wave Life Sciences Reports Q1 Loss Per Share Of $1.38

WAVE Life Sciences Reports Q4 Loss Per Share Of $1.65

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Wave Life Sciences Ltd

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington's disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

Industry

Biotechnology & Drugs

Contact Info

7 Straits View

#12-00, Marina One East Tower

018936

Singapore

+65.6.2363388

https://www.wavelifesciences.com/

Executive Leadership

Christian O. Henry

Independent Chairman of the Board

Paul B. Bolno

President, Chief Executive Officer, Director

David G. Gaiero

Interim Chief Financial Officer

Christopher John Francis

Senior Vice President - Corporate Development, Head of Emerging Areas

Kenneth Rhodes

Senior Vice President - Therapeutics Discovery

Key Stats

2.13 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-3.850

2018

-5.060

2019

-5.720

2020(E)

-3.666
Price To Earnings (TTM)
--
Price To Sales (TTM)
44.16
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-110.16
Return on Equity (TTM)
-66.33

Latest News

Latest News

BRIEF-Wave Life Sciences Reports Q1 Loss Per Share Of $1.38

* WAVE LIFE SCIENCES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Wave Life Sciences to return $7.2 million government payroll loan

Wave Life Sciences <WVE.O> said it will return a $7.2 million loan granted under the Payroll Protection Program (PPP), the latest company to do so following new guidance from the U.S Treasury Department.

Wave Life Sciences to return $7.2 mln PPP loan

Wave Life Sciences said on Friday it will return a $7.2 million loan granted under the Payroll Protection Program (PPP), the latest company to do so following new guidance from the U.S Treasury Department.

BRIEF-WAVE Life Sciences Reports Q4 Loss Per Share Of $1.65

* WAVE LIFE SCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Wave Life Sciences Ltd Says On February 6, Co Implemented A Cost Reduction Plan

* WAVE LIFE SCIENCES LTD - ON FEBRUARY 6, CO IMPLEMENTED A COST REDUCTION PLAN

BRIEF-Wave Life Sciences Reports Qtrly Loss Per Share $1.26

* WAVE LIFE SCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Wave Life Sciences And Deep Genomics Form Collaboration To Discover Therapies For Genetic Neuromuscular Disorders

* WAVE LIFE SCIENCES AND DEEP GENOMICS FORM COLLABORATION TO DISCOVER NOVEL THERAPIES FOR GENETIC NEUROMUSCULAR DISORDERS

BRIEF-Wave Life Ended 2017 With $142.5 Mln In Cash, Equivalents

* WAVE LIFE SCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Wave Life Sciences And Takeda Form Strategic Collaboration To Advance Therapies For Central Nervous System Disorders

* WAVE LIFE SCIENCES AND TAKEDA FORM GLOBAL STRATEGIC COLLABORATION TO ADVANCE THERAPIES FOR CENTRAL NERVOUS SYSTEM DISORDERS

BRIEF-Wave Life Sciences Reports Data From Preclinical Studies Testing WVE-3972-01

* WAVE LIFE SCIENCES - ANNOUNCED DATA FROM PRECLINICAL STUDIES OF WVE-3972-01 FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA

BRIEF-Wave Life Sciences Q3 net loss of $26.1 million

* Wave Life Sciences reports third quarter 2017 financial results and provides business update

BRIEF-Wave Life Sciences opens new 90,000 square foot manufacturing facility

* Wave Life Sciences Ltd - public opening of its new 90,000 square foot manufacturing facility and office space in Lexington, Massachusetts Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up